Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Capital Expenditures (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Capital Expenditures for 12 consecutive years, with -$127000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures fell 768.42% year-over-year to -$127000.0, compared with a TTM value of $99000.0 through Sep 2025, up 136.8%, and an annual FY2024 reading of $310000.0, up 313.33% over the prior year.
  • Capital Expenditures was -$127000.0 for Q3 2025 at CytomX Therapeutics, down from $27000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.3 million in Q3 2021 and bottomed at -$1.6 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $25947.4, with a median of $48000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures crashed 2608.11% in 2021, then soared 1883.33% in 2025.
  • Year by year, Capital Expenditures stood at -$1.3 million in 2021, then dropped by 21.16% to -$1.6 million in 2022, then soared by 67.85% to -$499000.0 in 2023, then soared by 116.03% to $80000.0 in 2024, then tumbled by 258.75% to -$127000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CTMX at -$127000.0 in Q3 2025, $27000.0 in Q2 2025, and $119000.0 in Q1 2025.